Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Strength Changes topic
No spam. Unsubscribe anytime.
FDA approves 30 mg fluoxetine suitability petition, denies 15 mg after labeling concerns
Summary
FDA staff described criteria for strength-change petitions and cited petition 2025p2077: the agency granted a 30 mg fluoxetine petition as the RLD dosing range supported it, and denied 15 mg because it lacked RLD dosing or clinical support.
Commander Andrew Fine laid out how FDA assesses strength-change petitions, focusing on whether the RLD labeling mentions the strength, allows dosing ranges or titration, and whether the proposed strength would necessitate new administration or dosing instructions.
To illustrate, Fine described petition 2025p2077 seeking 15 mg and 30 mg fluoxetine capsules. "We approve the 30 milligram strength because there's a clear dosing range and flexibility within the RLD labeling..." he said, and explained the RLD lists dosing in a 20—60 mg range (with higher doses tolerated), which supported the 30 mg approval.
Fine said the 15 mg strength was denied because RLD labeling explicitly described initiation and escalation (10 mg then 20 mg) and did not mention 15 mg; the safety and effectiveness of 15 mg therefore were not established. "Therefore, we issued partial grant approval for 30 milligrams and denial of the 15," he said.
Fine emphasized that approvals hinge on whether RLD labeling or special-population instructions imply the requested strength; when labeling lacks such support, denial is more likely unless additional evidence addresses safety and effectiveness.
